The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | Prophylactic treatment for CAR T-cell toxicity shows promising results
For CAR T-cell therapy to become mainstream, the management of related toxicities needs to be addressed. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses data being presented at the meeting for an additional cohort of the ZUMA-1 study (NCT02348216), investigating the use of tocilizumab for prophylaxis of the primary side effects of axicabtagene ciloleucel (axi-cel; KTE-C19). Dr Lin highlights the results of this treatment in regards to reducing the severity and/or incidence of cytokine release syndrome and neurotoxicity.
